GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors

Status:
Completed

Trial end date:
2020-05-13

Target enrollment:

Participant gender:

This is a Phase 1b study to explore the safety and efficacy of GX-I7 in combination with CPA in patients with metastatic or recurrent solid tumors.

Phase 1

Genexine, Inc.

Cyclophosphamide